HOT NEWS
European Commission Issues Positive Decision for Approval of Seroquel XR » AstraZeneca announced that the European Commission (EC) has issued a positive decision for the appro...
Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC » Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from t...
Global market launch of Daxas® (Roflumilast) kicks off in Germany » Stefan Brinkmann, Managing Director of Nycomed GmbH, kicked off the German market launch of Daxas® ...
A new era for patients with atrial fibrillation - Dabigatran etexilate at the fo... » The European Society of Cardiology (ESC) issued revised practice guidelines for the management of at...
Genetic substudy shows fewer major cardiovascular events with ticagrelor (BRILIN... » A new genetic substudy of PLATO (A Study of PLATelet Inhibition and Patient Outcomes) showed that th...
Shire Announces European Approval of VPRIV® (velaglucerase alfa) » Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today...
Bristol-Myers Squibb and Pfizer Inc Evaluate Unmet Need in Patients with Atrial ... » Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) report that preliminary results from...
GSK European Commission amends licence for Cervarix® » GlaxoSmithKline (GSK) confirmed that the European Commission has granted Marketing Authorisation to ...
Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial » Amgen (Nasdaq: AMGN) announced top-line results from a randomized Phase 3 trial evaluating Vectibix(...
Pfizer Reports Second-Quarter 2010 Results » Pfizer Inc. (NYSE: PFE) has reported financial results for second-quarter 2010. Since the acquisitio...
Novo Nordisk
Novo NordiskNovo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Novo Nordisk RSS Channel
Title Filter     Display # 
# Article Title Hits
1 Novo Nordisk partners with international scientific community for Victoza® cardiovascular outcomes trial 1151
2 The Lancet publishes new data demonstrating the superior efficacy of Victoza® (liraglutide) compared to Januvia® (sitagliptin) 1088
3 Danish companies join forces to compete for global talent 1180
4 Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue 1457
5 Novo Nordisk and Combine in research collaboration for the treatment of autoimmune diseases 1134
6 EFSD/Novo Nordisk partnership for diabetes research in Europe 1573
7 Novo Nordisk increased operating profit by 30% in the first nine months of 2009 1077
8 The Lancet publishes direct comparison study between liraglutide and exenatide 1730
9 Novo Nordisk and VLST Corporation announce collaboration agreement 1100
10 Urgent need for social and psychological support for young people with diabetes 1450
11 Novo Nordisk acquires intellectual property rights from Neose Technologies 731
 
Bookmark and Share